公开发行 - Celldex Therapeutics, Inc.宣布完成了之前宣布的公开发行的9,798,000股普通股，总共募集了约4.605亿美元[1] - Celldex的股票发行由Leerink Partners、TD Cowen、Guggenheim Securities和Cantor担任联席主承销商，LifeSci Capital和H.C. Wainwright & Co.担任联席经理[2] - Celldex的股票发行是根据之前在SEC注册的Form S-3文件进行的，可以通过SEC网站或联系Leerink Partners LLC和Cowen and Company, LLC获取相关文件[3] 公司背景 - Celldex是一家临床阶段的生物技术公司，致力于在肥大细胞生物学和转化性治疗开发领域引领科学，其产品包括能够激活人类免疫系统或直接影响关键途径的抗体类治疗药物[5] 前瞻性声明 - 公司声明中包含了"前瞻性声明"，提醒投资者注意实际结果可能与这些前瞻性声明中的预期有所不同，存在市场条件等风险[6] - 所有前瞻性声明都受到此警告通知的明确限制，投资者不应过度依赖这些前瞻性声明，公司没有义务更新这些前瞻性声明[7]

Celldex Therapeutics (CLDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Sinc ...

CLDX股价分析 - Celldex Therapeutics (CLDX)上周收盘价为$51.37，过去四周上涨了45.9%[1] - 分析师对CLDX的平均目标价为$65，显示了26.5%的上涨潜力[1] - 分析师对CLDX的短期目标价范围从$27到$80，标准偏差为$18.18[2] - 分析师对CLDX的盈利预期较之前更为乐观，这加强了看涨观点[4] - 分析师对CLDX盈利前景持续乐观，这可能是股票上涨的合理理由[9] 分析师目标价观点 - 研究表明，分析师的目标价很少能准确预测股价走势[5] - 分析师通常会设定过于乐观的目标价，以激发对公司股票的兴趣[6] - 分析师对股价走势有高度一致性的目标价，可能是进一步研究的好起点[7] - 投资者不应完全忽视目标价，但也不应仅凭此做出投资决策[8] CLDX股票评级 - CLDX当前的Zacks排名为2（买入），显示了股票短期潜在上涨[11]

HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock are being offered by the Company. The final terms of the ...

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.67 per share when it actually produced a loss of $0.81, delivering a surprise of -20.90%.Over the last four quarters, the ...

- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 -- Enrollment nearing completion in Phase 2 CIndU study; Data expected 2H 2024 -- Phase 2 PN study expected to start in early 2024; Positive Phase 1 PN data reported in oral presentation at WCI 2023 - HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial res ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3191702 State or other jurisdiction of incorporat ...

财务表现 - 2023年第四季度，CellDex Therapeutics, Inc.的营收总额为4,132,000美元，较去年同期增长了156.4%[27] - 2023年第四季度，CellDex Therapeutics, Inc.的研发支出为30,427,000美元，较去年同期增长了32.8%[27] - 2023年12月31日，CellDex Therapeutics, Inc.的现金、现金等价物和可市场交易证券总额为423,598,000美元，较去年同期增长了39.0%[28]

Barzolvolimab的疗效 - Celldex Therapeutics宣布了barzolvolimab在患有中度至重度慢性自发性荨麻疹（CSU）的患者中的积极12周结果[1] - Barzolvolimab在所有剂量水平上均显著改善UAS7（周荨麻疹活动评分）[3] - Barzolvolimab对于先前接受omalizumab治疗的患者和omalizumab-naïve患者的改善效果相似，与其独特的作用机制一致[3] Barzolvolimab的临床表现 - Barzolvolimab在患有omalizumab-refractory疾病的患者中表现出快速、持久且临床意义明显的反应[3] - Barzolvolimab在患有omalizumab-refractory疾病的患者中表现出与整体治疗人群相似的临床益处[6] Barzolvolimab的安全性 - Barzolvolimab具有良好的耐受性和有利的安全性概况，大多数不良事件为轻度至中度[7] Celldex Therapeutics的活动 - Celldex Therapeutics将于2月25日上午9:45举行网络研讨会，讨论这些结果[10] - Celldex Therapeutics是一家处于临床阶段的生物技术公司，致力于在肥大细胞生物学和转化性治疗药物开发领域引领科学[11]

HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 9:00 a.m. ET. A webcast of the presentation will be available on the "Events & Presentations" of the "Investors & Media" section of the Celldex website. A replay will be available for 30 days following the event. About Celldex Therapeutics, Inc.Cell ...